Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients

Autor: Isabel Font-Noguera, Conxa Borrás Almenar, José Luis Poveda Andrés, Rosario Menéndez Villanueva, Juan Eduardo Megías Vericat, José Andrés Román Iborra, Raúl Méndez, Eduardo López-Briz, Octavio Ballesta-López, Tomás Palanques-Pastor, Rubén Iglesias Gómez

Publikováno v: European Journal of Hospital Pharmacy
EUROPEAN JOURNAL OF HOSPITAL PHARMACY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Objectives To analyse the effectiveness and safety of baricitinib for severe COVID-19 in cytokine storm syndrome based on its potential role as an anti-inflammatory immunomodulator and inhibitor of viral endocytosis. Methods This was an observational

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfe88490b8bcf80bc73da33d6e5dd66
https://doi.org/10.1136/ejhpharm-2021-002741